KRAS and colorectal cancer: For colorectal cancer patients harboring KRAS mutations, 2D genome-wide CRISPR/Cas9 screens have been performed to investigate the genes required for sensitivity to the BCL/XL inhibitor (ABT-263, an anti-apoptotic protein), finding multiple regulators of the WNT signaling pathway as potential synthetic lethal targets [130].